• Aibing Wu, Jinmei Li, Kunpeng Wu, Yanli Mo, Yiping Luo, Haiyin Ye, Zongjiong Mai, Kangwen Guo, Yuzhou Wang, Shujun Li, Hualin Chen, Weiren Luo, and Zhixiong Yang.
• Cancer Center, Affiliated Hospital of Guangdong Medical University, No. 57 Peoples Avenue South, Zhanjiang 524001, Guangdong, China.
• Biomed. Pharmacother. 2016 Aug 1; 82: 290-7.

AbstractLarge tumor suppressor 2 (LATS2) plays significant roles in tumorigenesis and cancer progression. This study was aimed to analyze the correlation between LATS2 expression and clinicopathologic features and its prognostic significance in non-small cell lung cancer (NSCLC). LATS2 expression was examined in 73 NSCLC clinical specimens and 22 normal lung tissues using immunohistochemistry. Low levels of LATS2 protein were inversely associated with the T classification (P=0.001), N classification (P=0.005) and clinical stage (P=0.001) in NSCLC patients. Patients with lower LATS2 expression had a significantly shorter overall survival than patients with high LATS2 expression. Multivariate analysis suggested that low expression of LATS2 was an independent prognostic indicator (P=0.002) for the survival of patients with NSCLC. Furthermore, overexpression of LATS2 resulted in mobility inhibition in NSCLC cell lines A549 and H1299, and reduced protein level of matrix metalloproteinase-2 (MMP-2) and MMP-9. On the contrary, LATS2 siRNA treatment enhanced cell mobility and increased MMP-2 and MMP-9 protein expression level. In conclusion, low expression of LATS2 is a potential unfavorable prognostic factor and promoted cell invasion and migration in NSCLC. Copyright © 2016 Elsevier Masson SAS. All rights reserved.

45 keywords...

hide…